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Purpose/Objective: Dynamic MLC (DMLC) tracking has been 
shown to successfully mitigate the dosimetric effects of 
intra-fraction organ motion and restore the target dose for 
standard flat treatment beams. Going forward, the 
introduction of a new generation of treatment devices with 
restricted couch-shift possibilities (MR-Linac) raises the 
question of whether DMLC tracking with a non-flat flattening-
filter free (FFF) treatment beam is feasible and safe if a 
moving target is positioned at an offset to the isocenter. This 
study investigates the dosimetric accuracy of 6X FFF DMLC 
tracking for an SBRT treatment of a lung cancer case with a 
peripherally located target using step-and-shoot IMRT and 
VMAT deliveries on an Elekta Synergy linac. 
Materials and Methods: We generated two hypo-fractionated 
treatment plans (3x18 Gy) with similar dose conformity in the 
target (34 cm3 PTV) and a set of common planning constraints 
following the RTOG guidelines: a 15-beam step-and-shoot 
IMRT delivery, and a single arc VMAT delivery created in 
Pinnacle3 using SmartArc. The isocenter was shifted both 4 
cm laterally to the left and in the anterior direction. The 
shift was chosen so that the center of the PTV would coincide 
with the high-gradient region of the FFF beam profile. The 
treatment plans were then delivered - with and without 
tracking - to the Delta4 verification device, which was 
mounted on a 4d motion platform. The deliveries were 
repeated under three breathing conditions: no motion, sin(t), 
and sin(t) with a 1mm/min baseline drift. Motion was limited 
to the sup-inf direction with a peak-to-peak amplitude of 20 
mm and a time period of 4s. Dose measured for the static 
deliveries (no motion) were used as a reference to calculate 
the 1%/1mm, 2%/2mm and 3%/3mm gamma index for the 
DMLC deliveries.  
Results: For the tracked IMRT deliveries (550 MU/min, 
treatment time 13 min, Paddick conformity index CI=0.88), 
the 1%/1mm gamma index exceeded 79%, the 2%/2mm index 
exceeded 96% and it reached 100% at 3%/3mm for both 
sinusoidal trajectories. For the tracked VMAT deliveries (1100 
MU/min max dose rate, 4.5 min, CI=0.84), the 1%/1mm 
gamma index exceeded 97% and it reached 100% at 2%/2mm 
for all trajectories. This constituted a marked dosimetric 
improvement for all cases compared to the untracked 
deliveries. The maximum deterioration from regular sin(t) to 
sin(t) with drift was 8.3/2.3 percentage points at 1%/1mm for 
IMRT/VMAT, indicating a limited influence of the FFF beam 
gradient on the dosimetric accuracy if delivery times and 
thus drifts are small. 
Conclusions: We have presented initial evidence that 
indicates that the gradient of the Elekta Synergy FFF beam 
has a very limited impact on the dosimetric quality of DMLC 
tracking deliveries. Future work should include a larger 
collective of plans and sample different isocenter offsets. To 
facilitate the delivery of the VMAT plan under motion 
conditions, real-time VMAT DMLC tracking was implemented 
on a research version of the Synergy linac for the first time. 
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Purpose/Objective: A complementary dual-modality imaging 
system, consisting of an orthogonal kilovolt (kV) fluoroscopy 
system and an independent MV portal imager, was used to 
perform intra-and inter-fraction verification of real-time 
tumor tracking (RTTT) on 8 lung and 3 liver cancer patients. 
To the authors' knowledge, for the first time accuracy of 
real-time tumor tracking was quantified by direct MV imaging 
on a patient cohort and compared with the standard 
verification by log files and orthogonal kV imaging. 
Materials and Methods: First, the dual-modality verification 
system was validated against an independent optical camera 
system hereby assessing its geometrical accuracy and 
precision. For all patients, a fiducial marker was implanted 
to facilitate the detection of the internal tumor motion. 
During dual-modality RTTT verification, marker detection was 
performed on both orthogonal kV X-ray (0.5 Hz) and planar 
MV images (7 Hz) to determine the internal position of the 
lesion. Tracking errors (TE) were defined by the difference 
between tumor position (related to the marker position) and 
the tracking field position. For the 3D reconstructed kV 
marker position, gimbals log files were used to retreive the 
tracking MV field position (XR-log file method). For MV 
images, a template-matching was performed using the 
reference MLC outline from planning. For each patient, the 
95th percentile TE on the beams-eye view (BEV-TE95) with 
EPID (EPID-PART) and XR-log file (XRlog-PART) for the part of 
the MV beams that contained a visible MV marker was 
calculated. For the total treatment, BEV-TE95 and 95th 
percentile TE in 3D (3D-TE95) were quantified using XR-log file 
information (XRlog-TOT). 
Results: Validation based on the optical camera system 
resulted in a sub-millimeter accuracy of -0.15±0.44 mm (PAN) 
and 0.29±0.35 mm (TILT) for the XR-log file method while TE 
were reproduced with a lower precision on EPID, i.e. -
0.25±1.2 mm (PAN) and 0.35±1.1 mm (TILT). Results of dual-
modality (EPID versus XRlog) verification of RTTT on patients 
are listed in table 1. BEV-TE95 between EPID-PART and 
XRlog-PART were not significantly different (paired t-test; 
p>0.05). Intra- and inter-fraction TE variations between both 
modalities (EPID, XRlog) were very similar. Resulting PTV 
margins did not differ between EPID and XRlog TE. Due to low 
marker contrast for particular MV beams (depending on tissue 
thickness along the beam axis), EPID RTTT verification was 
feasible for 65% of the treatment beams, with a strong 
advantage for beams orientated around the anterior-
posterior axis.  
